Frankfurt
23.10.26 | 08:04
0,550 Euro
-5,50 % -0,032
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | AlzeCure Pharma to Present at Aktiespararna in Stockholm on 14 October | 289 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / October 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.09. | AlzeCure Pharma to Present at Swiss Nordic Bio 2026 in Zurich | 337 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease... ► Artikel lesen | |
| 18.09. | AlzeCure Pharma Publishes Updated Company Presentation Following the Eli Lilly and QuantumCell Agreements | 487 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 08.09. | AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15 | 365 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 27.08. | AlzeCure Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference on September 2 | 553 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - June 2026 | 219 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2026 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During... ► Artikel lesen | |
| 18.08. | AlzeCure Pharma: AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly | 1.597 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 12.08. | AlzeCure Pharma: AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell | 587 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 12, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 03.08. | AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell | 408 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 3, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered... ► Artikel lesen | |
| 02.07. | AlzeCure Pharma: Final Outcome of AlzeCure's Rights Issue | 650 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 3 | Pharmaceutical Technology | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| 01.07. | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| 01.07. | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| 01.07. | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 759 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 29.06. | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 711 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 652 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 523 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 15.06. | Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 342 | GlobeNewswire | With effect from June 16, 2026, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including June 25, 2026.
... ► Artikel lesen | |
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 7 | Pharmaceutical Technology |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 474,35 | -0,62 % | 115 Millionen US-Dollar mit einer Zelltherapie: Warum Mesoblast, Vertex und NurExone Zellen und Exosomen unterschiedlich nutzen | ||
| VIATRIS | 16,620 | +0,90 % | FDA Approves Viatris' RYZUMVI For Presbyopia Treatment | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.RYZUMVI... ► Artikel lesen | |
| ALTIMMUNE | 1,930 | 0,00 % | Altimmune präsentiert Daten zu Pemvidutide bei Lebererkrankungen auf AASLD-Kongress | ||
| SELLAS LIFE SCIENCES | 10,200 | +0,49 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| OPKO HEALTH | 1,440 | -1,37 % | Labcorp To Acquire Select BioReference Health Assets From OPKO Health For Up To $872 Million | ||
| JAGUAR HEALTH | 2,160 | +0,47 % | Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder | Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 15,360 | -0,55 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,360 | +0,85 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| LIPOCINE | 1,460 | 0,00 % | Lipocine Inc. - 8-K, Current Report | ||
| ACLARIS THERAPEUTICS | 3,532 | +3,03 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory... ► Artikel lesen | |
| PHOTOCURE | 4,600 | -2,13 % | Photocure ASA - New CFO Appointed | ||
| EUROBIO SCIENTIFIC | 24,200 | 0,00 % | Eurobio Scientific: Results for the first semester of fiscal year 2026 | RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2026 Revenue up 4.5% to 84.5 M€ Proprietary products account for 37% of revenue46% of revenue generated outside France Free cash flow of €4 million after... ► Artikel lesen | |
| MEDICURE | 2,720 | 0,00 % | Medicure, Inc.: Medicure Announces Grant of Stock Options | WINNIPEG, MB / ACCESS Newswire / October 1, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,550 Euro und damit -5,50 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.